contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


analyst-interview-in-swedish-with-ziccums-ceo-following-the-release-of-q3-2024-report

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Ziccum is a Swedish pharmaceutical company that develops new preparations of biological medicines. With the company's patented LaminarPace technology, dry preparation forms are developed for products that are currently available in liquid form. Most of the business is found around the Nordic region, and in addition to the main business, the company offers various related products. The company's head office is in Lund. 

Ziccum

Watch Ziccum’s CEO Ann Gidner in a comprehensive interview with analyst Jonathan Furelid in Swedish on the highlights of Ziccum’s Q3 2024 report and the company’s current status.Ziccum’s CEO...

<div class="mfn-preamble"><p><strong>Watch Ziccum’s CEO Ann Gidner in a comprehensive interview with analyst Jonathan Furelid in Swedish on the highlights of Ziccum’s Q3 2024 report and the company’s current status.</strong></p></div><div class="mfn-body"><p>Ziccum’s CEO, Ann Gidner, shares a number of exciting developments, including an invitation to participate in a large international consortium with key industrial and academic partners, the on-going inhaled mRNA/LNP animal studies, and the current status of the collaboration with ReCode Therapeutics.</p><p>Please watch the entire interview here: <a rel="noopener" href="https://eur04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fyoutu.be%2F5fUJ-wSJGX8&amp;data=05%7C02%7CVassilev%40ziccum.com%7Ced6b069fd36d40f4a21e08dcf9b2e0b1%7Cea9ed72127c1478e8764813b2e7a70ae%7C0%7C0%7C638659793896852153%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=XKqmg59qabj2ZYKY6Vgfi8pRd%2BENrV7JCfZBUBS37e4%3D&amp;reserved=0">https://youtu.be/5fUJ-wSJGX8</a></p></div><div class="mfn-footer mfn-contacts mfn-a7e2690bb361"><p><strong class="mfn-heading-1">For more information about Ziccum, please contact:</strong></p><hr><p>Ann Gidner<br>CEO, Ziccum AB<br>Mail: gidner@ziccum.com<br>Mobile: +46 722140141</p><p>Jonas Ekblom<br>Chairman of the Board, Ziccum AB<br>Mail: ekblom@ziccum.com<br>Mobile: +46 736777540</p><p>Ziccum’s Certified Adviser is<br>Vator Securities AB</p></div><div class="mfn-footer mfn-about mfn-f6f38bef847c"><p><strong class="mfn-heading-1">About Ziccum</strong></p><hr><p>Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace® uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has been successfully applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application. Ziccum is listed on the Nasdaq First North Growth Market.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/8d8e47e7-a19b-4347-8c50-7f53a18305fd/analyst-interview-in-swedish-with-ziccums-ceo-following-the-release-of-q3-2024-report.pdf" class="mfn-generated mfn-primary">Analyst interview in Swedish with Ziccum's CEO following the release of Q3, 2024 report</a></p></div>

Analyst interview in Swedish with Ziccum's CEO following the release of Q3, 2024 report

Return on capital (ROE, ROI, ROIC, RONIC)

What does negative working capital mean and why is it a good thing?

Drug development investment: Value creation through M&As and licensing agreements

Income statement

Amazon and Costco in Sweden: A looming threat that Nordic retailers ignore at their peril

Stay up to date with our newsletter